218 related articles for article (PubMed ID: 35840818)
21. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing redefines the diagnosis of triple-negative myeloproliferative neoplasms.
Wu S; Luo P; Yu Y; Xiong B; Wang Y; Zuo X
Ann Hematol; 2022 Mar; 101(3):705-708. PubMed ID: 34518917
[No Abstract] [Full Text] [Related]
23. [Pathological characteristics of megakaryocytes in myeloproliferative neoplasms and their correlation with driver gene mutations].
Shi ZX; Zhang PH; Li B; Fang LH; Xu ZF; Qin TJ; Liu JQ; Hu NB; Pan LJ; Qu SQ; Liu D; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):798-805. PubMed ID: 33190435
[No Abstract] [Full Text] [Related]
24. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract][Full Text] [Related]
25. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
26. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
27. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
28. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
[TBL] [Abstract][Full Text] [Related]
29. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional configurations of myeloproliferative neoplasms.
Schischlik F
Int Rev Cell Mol Biol; 2022; 366():25-39. PubMed ID: 35153005
[TBL] [Abstract][Full Text] [Related]
31. Myeloproliferative Neoplasms with Monocytosis.
Morsia E; Gangat N
Curr Hematol Malig Rep; 2022 Feb; 17(1):46-51. PubMed ID: 34773576
[TBL] [Abstract][Full Text] [Related]
32. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
33. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
34. Targets in MPNs and potential therapeutics.
Levy G; Mambet C; Pecquet C; Bailly S; Havelange V; Diaconu CC; Constantinescu SN
Int Rev Cell Mol Biol; 2022; 366():41-81. PubMed ID: 35153006
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
Zhang L; Ye X; Luo S; Xu X; Wang S; Jin K; Zheng Y; Zhu X; Chen D; Jin J; Huang J
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2383-2392. PubMed ID: 35731275
[TBL] [Abstract][Full Text] [Related]
36. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
38. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Dec; 149(12):1687-1693. PubMed ID: 35735335
[TBL] [Abstract][Full Text] [Related]
39. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Nov; 149(11):1532-1538. PubMed ID: 35735314
[TBL] [Abstract][Full Text] [Related]
40. The roles of sex and genetics in the MPN.
Moliterno AR; Braunstein EM
Int Rev Cell Mol Biol; 2022; 366():1-24. PubMed ID: 35153002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]